<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523965</url>
  </required_header>
  <id_info>
    <org_study_id>VLCombo 07</org_study_id>
    <nct_id>NCT00523965</nct_id>
  </id_info>
  <brief_title>Combination Therapy in Indian Visceral Leishmaniasis</brief_title>
  <official_title>A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banaras Hindu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rajendra Memorial Research Institute of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banaras Hindu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale

      The overall objective of this trial is to identify a safe and effective combination,
      (co-administration) short course treatment for the treatment of VL which could be easily
      deployed in a control programme. The hypothesis is that the combination treatment is as
      effective or better than the 5 mg/kg single dose of AmBisome and will reduce the risk of
      parasite resistance occurring. Safety and tolerability should be such that the combination
      can be easily deployed.

      Objective

      The specific primary and secondary objectives are as follows:

      Primary objective:

      To identify a short course combination treatment regimen which is at least as effective as a
      single dose of AmBisome 5mg/kg

      Secondary objective:

      To compare safety and tolerability of the various treatments measured by vital signs, blood
      biochemistry, (renal and liver function tests) haematology, spontaneous and elicited adverse
      event reporting

      Primary Endpoint:

      The primary efficacy endpoint variable is parasitological clearance 2 weeks after start of
      treatment with no relapse during follow up and no clinical signs or symptoms of VL at 6
      months post treatment.

      Parasitology is only carried out at any time during follow-up or at six months post treatment
      if there are signs or symptoms of VL infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final cure at six month follow up</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cure at six month follow up</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial cure at the end of treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">624</enrollment>
  <condition>Leishmaniasis, Visceral</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AmBisome 5 mg/kg iv infusion over 2 h x 1 day (single dose) + oral miltefosine 50mg once daily (&lt; 25 kg body weight) or twice daily ( &gt; 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 7 days on day 2-8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral miltefosine 50mg once daily (&lt; 25 kg body weight) or twice daily ( &gt; 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amphotericin B deoxycholate at 1 mg/kg every other day for 15 infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amphotericin B deoxycholate</intervention_name>
    <description>Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Amphotericin B with Miltefosine</intervention_name>
    <description>Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or &gt; 25 kg Miltefosine 50 mg once daily if patient weighs &lt;25 mg</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Amphotericin B and Paromomycin Sulfate</intervention_name>
    <description>AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>miltefosine + Paromomycin sulfate</intervention_name>
    <description>oral miltefosine 50mg once daily (&lt; 25 kg body weight) or twice daily ( &gt; 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 5 years old with symptoms and signs of kala-azar (fever, weight loss,
             splenomegaly) and parasites demonstrated by microscopy in splenic aspirate smear

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Individuals seropositive to HIV or individuals with a serious concurrent infection
             such as tuberculosis or bacterial pneumonia.

          -  Women of child-bearing age will be counseled about adequate birth control during and
             for three months after miltefosine treatment and provided with a satisfactory method
             of contra-ception.

          -  Granulocyte count &lt; 1,000/mm3, hemoglobin &lt; 5 g/dL or platelet count &lt; 40,000/mm3

          -  Hepatic transaminases or total bilirubin greater than three times normal

          -  Serum creatinine &gt; 2.0 mg/dL

          -  Prothrombin time &gt; 5 seconds above control

          -  Inability of subject or guardian to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Sundar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Medical Sciences, Banaras HIndu University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P K Sinha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rajendra Memorial Research Insititute of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kala-azar Medical Research Center</name>
      <address>
        <city>Muzaffarpur</city>
        <state>Bihar</state>
        <zip>842001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shyam Sundar</name_title>
    <organization>Drugs for Neglected Diseases Initiative</organization>
  </responsible_party>
  <keyword>Kala-azar</keyword>
  <keyword>miltefosine</keyword>
  <keyword>liposomal amphotericin B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Paromomycin</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
    <mesh_term>Miltefosine</mesh_term>
    <mesh_term>Amphotericin B, deoxycholate drug combination</mesh_term>
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

